Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

Novo's Amycretin delivers great Phase 2 results
Novo Nordisk Logo

Novo Nordisk's new GLP1 Receptor Agonist Amycretin recently completed phase 2 trials and delivered fantastic results:

News Details

The results are pretty amazing:

When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively.

On a dose of 5mg after 28 weeks (just 6 months), 16% body weight loss is nothing short of amazing.

Amycretin isn't the only new GLP1 on the market though – let's dive in and see how it compares to other formulations under development.

What is Amycretin?

We've covered Amycretin before:

Novo’s new GLP1: Amycretin
Novo has a new drug it’s working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.

Amycretin is a dual agonist (similar to but different from Tirzepatide, which is a dual agonist) being developed by Novo Nordisk. It influences the following hormones in your body:

  • Amylin
  • GLP1

The side effects seem to be largely unchanged from Semaglutide and Tirzepatide, with no new drastic negative side effects being introduced so far.

While the results from the trial have not been released yet in full, it serves as another chance to

How does Amycretin compare to other new drugs?

There are a few new GLP1s on the horizon:

  • Retatrutide (Eli Lilly)
  • MariTide/AMG-133 (Amgen)
  • Danuglipron (Pfizer)

Amycretin vs. Retatrutide

Retatrutide is a triple agonist – but more agonists does not always mean better performance. A relatively high dosage of 12mg of Retatrutide "only" produced 17% body weight loss at 24 weeks.

A new GLP1: Retatrutide
Is mimicking more hormones better? Let’s find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist

Amycretin vs. MariTide

MariTide produced 20% of weight loss after 52 weeks. While 20% body weight loss after just one year is impressive, the fact that they only made available a 52 week stat likely means the drug did not do impressively on a shorter timescale.

Amgen’s GLP1: AM-133
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it’s got any promise.

Amycretin vs Danuglipron

Danuglipron delivered less than stellar results the last time it was tested:

Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks

The study was also relatively small, but the variability in outcomes and the lack of loss near 26 weeks compared to Amycretin makes Amycretin the clear choice.

Pfizer is in the game, but it's likely going to take a bit more ingenuity/engineering to reach the current phase 2 results produced by Amycretin.

Clearly the average consumer is spoiled for choice when it comes to new GLP1s under development, but Amycretin is indeed a powerful competitor.

What are the adverse side effects?

One thing we don't have enough information on are the changes in occurrence or frequency of adverse side effects.

Unfortunately the entirety of the research is not yet published publicly, so we can't know this, but given that prior trials of Amycretin did not surface completely new negative side effects, and the press release did not mention any, there may only be issues of increased severity (if any) of existing side effects.

We're looking forward to the full release of the trial data.

Share on Tumblr
Share on Pinterest
Share on LinkedIn
Share on Reddit